We use cookies on our site to analyze traffic, enhance your experience, and provide you with tailored content.

For more information visit our privacy policy.

Common use of Designation, Amount and Par Value Clause in Contracts

Designation, Amount and Par Value. The series of preferred stock shall be designated as its Series A Convertible Preferred Stock (the “Preferred Stock”) and the number of shares so designated shall be up to 2,000,000 (which shall not be subject to increase without the written consent of the holders of a majority of the then outstanding Preferred Stock (each, a “Holder” and collectively, the “Holders”)). Each share of Preferred Stock shall have a par value of $0.0001 per share and a stated value equal to $10.00, subject to increase set forth in Section 3 below (the “Stated Value”).

Appears in 2 contracts

Samples: Subscription Agreement (Denali SPAC Holdco, Inc.), Subscription Agreement (Denali Capital Acquisition Corp.)

Designation, Amount and Par Value. The series of preferred stock shall be designated as its Series A Convertible Preferred Stock (the “Preferred Stock”) and the number of shares so designated shall be up to 2,000,000 17,391,300 (which shall not be subject to increase without the written consent of the holders of a majority in interest of the then outstanding Preferred Stock (each, a “Holder” and collectively, the “Holders”)). Each share of Preferred Stock shall have a par value of $0.0001 per share and a stated value equal to $10.0011.50, subject to increase set forth in Section 3 below (the “Stated Value”).

Appears in 2 contracts

Samples: Subscription Agreement (CONX Corp.), Subscription Agreement (CONX Corp.)

Designation, Amount and Par Value. The series of preferred stock shall be designated as its Series A 10% Convertible Preferred Stock (the “Preferred Stock”) and the number of shares so designated shall be up to 2,000,000 12,000 (which shall not be subject to increase without the written consent of all of the holders of a majority of the then outstanding Preferred Stock (each, a “Holder” and collectively, the “Holders”)). Each share of Preferred Stock shall have a par value of $0.0001 0.001 per share and a stated value equal to $10.001,000, subject to increase set forth in Section 3 3(a) below (the “Stated Value”).

Appears in 2 contracts

Samples: Securities Purchase Agreement (NewCardio, Inc.), Share Exchange Agreement (NewCardio, Inc.)

Designation, Amount and Par Value. The series of preferred stock shall be designated as its Series A 12% Convertible Preferred Stock (the “Preferred Stock”) and the number of shares so designated shall be up to 2,000,000 6,000,000 (which shall not be subject to increase without the written consent of all of the holders of a majority of the then outstanding Preferred Stock (each, a “Holder” and collectively, the “Holders”)). Each share of Preferred Stock shall have a par value of $0.0001 0.01 per share and a stated value equal to $10.001.00, subject to increase set forth in Section 3 below (the “Stated Value”).

Appears in 1 contract

Samples: Securities Purchase Agreement (BioRestorative Therapies, Inc.)

Designation, Amount and Par Value. The series of preferred stock shall be designated as its the Corporation’s Series A C 9% Convertible Preferred Stock (the “Preferred Stock”) and the number of shares so designated shall be up to 2,000,000 4,200 (which shall not be subject to increase without the written consent of all of the holders of a majority of the then outstanding Preferred Stock (each, a “Holder” and collectively, the “Holders”)). Each share of Preferred Stock shall have a par value of $0.0001 0.001 per share and a stated value equal to $10.001,000, subject to increase set forth in Section 3 below (the “Stated Value”).

Appears in 1 contract

Samples: Securities Purchase Agreement (BioSig Technologies, Inc.)

Designation, Amount and Par Value. The series of preferred stock shall be designated as its Series A B 17.38% Convertible Preferred Stock (the “Preferred Stock”) and the number of shares so designated shall be up to 2,000,000 105,204 (which shall not may be subject to increase increased without the written consent of all of the holders of a majority of the then outstanding Preferred Stock (each, a “Holder” and collectively, the “Holders”)). Each share of Preferred Stock shall have a par value of $0.0001 per share and a stated value equal to $10.001,000, subject to increase set forth in Section 3 below (the “Stated Value”).

Appears in 1 contract

Samples: Securities Purchase Agreement (Amyris, Inc.)

Designation, Amount and Par Value. The series of preferred stock shall be designated as its Series A F 8% Convertible Preferred Stock (the “Series F Preferred Stock”) and the number of shares so designated shall be up to 2,000,000 5,001 (which shall not be subject to increase without the written consent of all of the holders of a majority of the then outstanding Series F Preferred Stock (each, a “Holder” and collectively, the “Holders”)). Each share of Series F Preferred Stock shall have a par value of $0.0001 0.001 per share and a stated value equal to $10.001,000, subject to increase set forth in Section 3 below (the “Stated Value”).

Appears in 1 contract

Samples: Securities Purchase Agreement (Attis Industries Inc.)

Designation, Amount and Par Value. The series of preferred stock shall be designated as its Series A C 9.00% Convertible Junior Preferred Stock (the “Series C Preferred Stock”) and the number of shares so designated shall be up to 2,000,000 75,000.0000 (which shall not be subject to increase without the written consent of all of the holders of a majority of the then outstanding Series C Preferred Stock (each, a “Holder” and collectively, the “Holders”)). Each share of Series C Preferred Stock shall have a par value of $0.0001 per share and a stated value equal to $10.00750.00, subject to increase set forth in Section 3 below (the “Stated Value”).

Appears in 1 contract

Samples: Securities Purchase Agreement (AzurRx BioPharma, Inc.)

Designation, Amount and Par Value. The series of preferred stock shall be designated as its Series A B 5% Convertible Preferred Stock (the “Preferred Stock”) and the number of shares so designated shall be up to 2,000,000 20,000 (which shall not be subject to increase without the written consent of all of the holders of a majority of the then outstanding Preferred Stock (each, a “Holder” and collectively, the “Holders”)). Each share of Preferred Stock shall have a par value of $0.0001 0.001 per share and a stated value equal to $10.001,080.00 per share, subject to increase set forth in Section 3 below (the “Stated Value”).

Appears in 1 contract

Samples: Securities Purchase Agreement (Innovation Pharmaceuticals Inc.)

Designation, Amount and Par Value. The series of preferred stock shall be designated as its Series A Convertible Preferred Stock (the “Series A Preferred Stock”) and the number of shares so designated shall be up to 2,000,000 4,179 (which shall not be subject to increase without the written consent of all of the holders of a majority of the then outstanding Series A Preferred Stock (each, a “Holder” and collectively, the “Holders”)). Each share of Series A Preferred Stock shall have a par value of $0.0001 0.001 per share and a stated value equal to $10.001,000, subject to increase set forth in Section 3 below (the “Stated Value”).

Appears in 1 contract

Samples: Securities Purchase Agreement (Cerecor Inc.)

Designation, Amount and Par Value. The series of preferred stock shall be designated as its Series A __ Convertible Preferred Stock (the "Preferred Stock") and the number of shares so designated shall be up to 2,000,000 40,617_ (which shall not be subject to increase without the written consent of the holders of a majority of the then outstanding holders of the Preferred Stock (each, a "Holder" and collectively, the "Holders")). Each share of Preferred Stock shall have a par value of $0.0001 0.10 per share and a stated value equal to $10.001,000, subject to increase set forth in Section 3 below (the "Stated Value").

Appears in 1 contract

Samples: Securities Exchange Agreement (STRATA Skin Sciences, Inc.)

Designation, Amount and Par Value. The series of preferred stock shall be designated as its Series A 17.38% Convertible Preferred Stock (the “Preferred Stock”) and the number of shares so designated shall be up to 2,000,000 22,140 (which shall not may be subject to increase increased without the written consent of all of the holders of a majority of the then outstanding Preferred Stock (each, a “Holder” and collectively, the “Holders”)). Each share of Preferred Stock shall have a par value of $0.0001 per share and a stated value equal to $10.001,000, subject to increase set forth in Section 3 below (the “Stated Value”).

Appears in 1 contract

Samples: Securities Purchase Agreement (Amyris, Inc.)